CLINICAL TRIALS PROFILE FOR TAK-788

Clinical Trials for TAK-788

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02716116 ↗	A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer	Recruiting	Takeda	Phase 1/Phase 2	This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment.
NCT02716116 ↗	A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer	Recruiting	Ariad Pharmaceuticals	Phase 1/Phase 2	This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment.
NCT02716116 ↗	A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer	Recruiting	Millennium Pharmaceuticals, Inc.	Phase 1/Phase 2	This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment.

Clinical Trial Conditions for TAK-788

Condition Name

Condition Name
Intervention	Trials
Healthy Volunteers	6
Carcinoma, Non-Small-Cell Lung	2
Hepatic Impairment	1

Condition MeSH

Condition MeSH
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	5
Lung Neoplasms	4
Liver Diseases	1

Clinical Trial Locations for TAK-788

Trials by Country

Trials by Country
Location	Trials
United States	39
Japan	18
Italy	9
Germany	8
China	8

Trials by US State

Trials by US State
Location	Trials
Florida	4
Arizona	3
California	2
Nebraska	2
Washington	2

Clinical Trial Progress for TAK-788

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	4
Recruiting	4
Active, not recruiting	2

Clinical Trial Sponsors for TAK-788

Sponsor Name

Sponsor Name
Sponsor	Trials
Millennium Pharmaceuticals, Inc.	8
Takeda	4
Ariad Pharmaceuticals	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	13